PNC-27 (p53-Derived Research Peptide)
PNC-27 (10mg) is a nominal-quantity p53-derived synthetic peptide for in-vitro HDM-2 interaction and membrane-associated pathway research. In-stock orders receive same-day dispatch from Victoria after payment confirmation, with tracked Australia Post Express shipping Australia-wide.
This product is sold strictly for in-vitro laboratory research purposes only. It is not a therapeutic good, is not approved by the TGA, and is not intended for human or animal consumption, injection, or any diagnostic or therapeutic use.
p53-derived peptide · HDM-2 and membrane-associated research
PNC-27 is a synthetic 32-amino-acid research peptide that combines p53 residues 12–26 with a membrane-residency sequence. It is also written PNC 27 or PNC27. Published preclinical work examines its association with HDM-2 (human MDM2) and membrane disruption in selected cell models. This listing identifies PNC-27 with a nominal 10mg quantity for in-vitro laboratory research only, not a cancer medicine, clinical-trial product or personal-use formulation. Buy PNC-27 online in Australia from Australian-held inventory, subject to current stock, with Victorian dispatch. The material is not for human or animal use.
Also referred to in research or catalogue references as PNC 27, PNC27, PNC-27 peptide, p53-derived PNC-27 peptide.
PNC-27 is a 32-amino-acid synthetic peptide. The published construct contains residues 12–26 from the HDM-2-binding region of p53 joined to a membrane-residency peptide at its carboxyl end. It is therefore not p53 itself and does not replace the full p53 protein. The terms PNC-27, PNC 27 and PNC27 are spelling variants used for this research peptide.
HDM-2 is a name used in the cited PNC-27 literature for the human MDM2 protein. The p53-derived segment was studied because it resembles a region involved in p53–HDM-2 binding. Experimental work examined whether PNC-27 associates with HDM-2 detected in the membranes of particular cancer-cell models. This is a model-specific research question, not evidence that all tumour cells or healthy tissues behave the same way.
In the cited cell-line experiments, investigators reported PNC-27 co-localisation with membrane-associated HDM-2 and membrane pore formation or cell lysis in the models tested. A separate K562 leukemia-cell-line experiment examined similar findings in a p53-null setting. These observations help frame mechanistic research, but cell death in cultured cells does not establish an effective or safe treatment in people.
The cited K562 work used cells reported to lack p53 expression, yet researchers observed PNC-27 association with HDM-2 and cell death in that system. For that model, the authors described the finding as p53-independent. This should not be simplified into a claim that PNC-27 restores p53 function, and it does not establish a therapeutic mechanism outside the experimental conditions.
No product-specific LabDoc report is currently published for this listing. Review available Quality/COA documentation; a report for another product does not verify this material.
The 10mg in this product listing is the nominal total quantity supplied for this product. It is not a dose, a liquid concentration, a potency result or a personal-use schedule. The product listing does not provide a product-specific concentration, actual measured content or preparation method. Those facts should not be inferred from another supplier’s vial, another PNC-27 strength or a public protocol.
No product-specific LabDoc report is currently published for this listing. Review available Quality/COA documentation; a report for another product does not verify this material.
PNC-27 is also written PNC 27 or PNC27. It is a synthetic p53-derived 32-amino-acid research peptide, not the full p53 protein. The spelling variants do not establish that materials from different suppliers, batches or formulations are analytically equivalent.
Published preclinical studies examine PNC-27 in relation to HDM-2, also called human MDM2, and membrane-associated cell effects in selected experimental models. These studies support a laboratory research context only; they do not demonstrate a cancer treatment, patient benefit or a predictable outcome from this listing.
No. PNC-27 contains a segment derived from p53 but is not the full p53 protein. PNC-28 is a related but distinct experimental peptide. Sequence, study result, formulation and analytical evidence should remain attached to the specific molecule and material actually examined.
It states the listed nominal quantity for this product. It is not a dose, concentration, administration schedule or claim about actual measured content. The listing does not provide reconstitution, injection, cycle, stability or handling instructions because none were supplied and they would not be validated for this material.
No product-specific LabDoc report is currently published for this listing. Review available Quality/COA documentation; a report for another product does not verify this material.
This PNC-27 research listing can be ordered online from Australian-held inventory when stock is available. Orders dispatch from Victoria and ship within Australia via Australia Post Express, with tracking provided after dispatch. Delivery timing depends on the destination and carrier network; Express is not a guaranteed next-day service.
Scientific background reference
Scientific background is educational and separate from product-specific documentation. Neither establishes personal-use suitability or a clinical result for this research material.